NEW YORK − Hutchison Medipharma, a subsidiary of Chi-Med, said on Friday that it has started a Phase I trial in China for HMPL-306 in patients with IDH1 and IDH2-mutated relapsed or refractory myeloid leukemia or neoplasms and has dosed the first patient.